AUTHORS' CONCLUSIONS:Although reductions in all-cause mortality, composite endpoints and revascularisations were found with no excess of adverse events, there was evidence of selective reporting of outcomes, failure to report adverse events and inclusion of people with cardiovascular disease. Only limited evidence showed that primary prevention with statins may be cost effective and improve patient quality of life. Caution should be taken in prescribing statins for primary prevention among people at low cardiovascular risk.
From a meta-analysis -- Pharmaceutical companies doctored data.
"The authors of the new Cochrane meta-analysis, led by Dr Fiona Taylor (London School of Hygiene and Tropical Medicine, UK), issued a press release questioning the benefit of statins in primary prevention and suggesting that the previous data showing benefit may have been biased by industry-funded studies."
Note the close ties they have with the drug companies -- Pfizer, Merck, IVAX Pharmaceuticals, AstraZeneca, Johnson & Johnson -- that produce statins.
The ties encompass the following: honoraria fees from the companies, research grants from the companies, unrestricted institutional grants from the companies, consultant appointments from the companies, speakers for the companies, and ownership of stock in the companies.View Thread